JP2020532947A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532947A5 JP2020532947A5 JP2019559021A JP2019559021A JP2020532947A5 JP 2020532947 A5 JP2020532947 A5 JP 2020532947A5 JP 2019559021 A JP2019559021 A JP 2019559021A JP 2019559021 A JP2019559021 A JP 2019559021A JP 2020532947 A5 JP2020532947 A5 JP 2020532947A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 316
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 73
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 49
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 40
- 238000006467 substitution reaction Methods 0.000 claims description 35
- 102000056982 human CD33 Human genes 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- -1 TMEM 30 (A) Proteins 0.000 claims description 21
- 230000001717 pathogenic effect Effects 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 210000004899 c-terminal region Anatomy 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 11
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- KZNQNBZMBZJQJO-UHFFFAOYSA-N 1-(2-azaniumylacetyl)pyrrolidine-2-carboxylate Chemical compound NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 claims description 10
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims description 10
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 10
- 108700030955 C9orf72 Proteins 0.000 claims description 9
- 102100029301 Guanine nucleotide exchange factor C9orf72 Human genes 0.000 claims description 9
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 9
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 244000052769 pathogen Species 0.000 claims description 7
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 5
- IVNJKQPHHPMONX-WCCKRBBISA-N 2-aminoacetic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N IVNJKQPHHPMONX-WCCKRBBISA-N 0.000 claims description 5
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 5
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 5
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 102100034452 Alternative prion protein Human genes 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims description 5
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims description 5
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 5
- 102000007372 Ataxin-1 Human genes 0.000 claims description 5
- 108010032963 Ataxin-1 Proteins 0.000 claims description 5
- 102000002785 Ataxin-10 Human genes 0.000 claims description 5
- 108010043914 Ataxin-10 Proteins 0.000 claims description 5
- 102000007371 Ataxin-3 Human genes 0.000 claims description 5
- 108010032947 Ataxin-3 Proteins 0.000 claims description 5
- 102000007368 Ataxin-7 Human genes 0.000 claims description 5
- 108010032953 Ataxin-7 Proteins 0.000 claims description 5
- 102100026565 Ataxin-8 Human genes 0.000 claims description 5
- 101710147490 Ataxin-8 Proteins 0.000 claims description 5
- 102000007370 Ataxin2 Human genes 0.000 claims description 5
- 108010032951 Ataxin2 Proteins 0.000 claims description 5
- 102000014461 Ataxins Human genes 0.000 claims description 5
- 108010078286 Ataxins Proteins 0.000 claims description 5
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 5
- 101150014718 C9orf72 gene Proteins 0.000 claims description 5
- 102100027207 CD27 antigen Human genes 0.000 claims description 5
- 102100038078 CD276 antigen Human genes 0.000 claims description 5
- 101710185679 CD276 antigen Proteins 0.000 claims description 5
- 101150013553 CD40 gene Proteins 0.000 claims description 5
- 102100025221 CD70 antigen Human genes 0.000 claims description 5
- 102000055006 Calcitonin Human genes 0.000 claims description 5
- 108060001064 Calcitonin Proteins 0.000 claims description 5
- 102000015833 Cystatin Human genes 0.000 claims description 5
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 5
- 108010016626 Dipeptides Proteins 0.000 claims description 5
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims description 5
- 102100031351 Galectin-9 Human genes 0.000 claims description 5
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims description 5
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 5
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims description 5
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 5
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 5
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 5
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 5
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 5
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 5
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims description 5
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 claims description 5
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 5
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 5
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 5
- 101000831286 Homo sapiens Protein timeless homolog Proteins 0.000 claims description 5
- 101000752245 Homo sapiens Rho guanine nucleotide exchange factor 5 Proteins 0.000 claims description 5
- 101000669511 Homo sapiens T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 claims description 5
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 5
- 101000795107 Homo sapiens Triggering receptor expressed on myeloid cells 1 Proteins 0.000 claims description 5
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 claims description 5
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 5
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 5
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 5
- 102000003839 Human Proteins Human genes 0.000 claims description 5
- 108090000144 Human Proteins Proteins 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 5
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 5
- 102000004877 Insulin Human genes 0.000 claims description 5
- 108090001061 Insulin Proteins 0.000 claims description 5
- 102000002698 KIR Receptors Human genes 0.000 claims description 5
- 108010043610 KIR Receptors Proteins 0.000 claims description 5
- 102000017578 LAG3 Human genes 0.000 claims description 5
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 5
- 102400001156 Medin Human genes 0.000 claims description 5
- 101800003015 Medin Proteins 0.000 claims description 5
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 5
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 108091000054 Prion Proteins 0.000 claims description 5
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 5
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 5
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 5
- 108010057464 Prolactin Proteins 0.000 claims description 5
- 102000003946 Prolactin Human genes 0.000 claims description 5
- 108090000292 RNA-binding protein FUS Proteins 0.000 claims description 5
- 102000003890 RNA-binding protein FUS Human genes 0.000 claims description 5
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 5
- 108700028909 Serum Amyloid A Proteins 0.000 claims description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 5
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 5
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 claims description 5
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 5
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 claims description 5
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 claims description 5
- 102100029681 Triggering receptor expressed on myeloid cells 1 Human genes 0.000 claims description 5
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 claims description 5
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims description 5
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 5
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 5
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 5
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 5
- 108090000848 Ubiquitin Proteins 0.000 claims description 5
- 102000044159 Ubiquitin Human genes 0.000 claims description 5
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 5
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 5
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 5
- PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 claims description 5
- 230000000692 anti-sense effect Effects 0.000 claims description 5
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 5
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 5
- 230000008499 blood brain barrier function Effects 0.000 claims description 5
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 5
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 5
- 229960004015 calcitonin Drugs 0.000 claims description 5
- 108050004038 cystatin Proteins 0.000 claims description 5
- 239000002934 diuretic Substances 0.000 claims description 5
- 230000001882 diuretic effect Effects 0.000 claims description 5
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 229940125396 insulin Drugs 0.000 claims description 5
- 210000004153 islets of langerhan Anatomy 0.000 claims description 5
- 210000000274 microglia Anatomy 0.000 claims description 5
- 229940097325 prolactin Drugs 0.000 claims description 5
- 230000003252 repetitive effect Effects 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims description 4
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 claims description 4
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 101150036449 SIRPA gene Proteins 0.000 claims description 4
- 102000004584 Somatomedin Receptors Human genes 0.000 claims description 4
- 108010017622 Somatomedin Receptors Proteins 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 3
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 238000010494 dissociation reaction Methods 0.000 claims description 3
- 230000005593 dissociations Effects 0.000 claims description 3
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 210000001616 monocyte Anatomy 0.000 claims description 3
- 210000000440 neutrophil Anatomy 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 2
- 235000002198 Annona diversifolia Nutrition 0.000 claims description 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 2
- 229930186217 Glycolipid Natural products 0.000 claims description 2
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 claims description 2
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims description 2
- 101000836877 Homo sapiens Sialic acid-binding Ig-like lectin 11 Proteins 0.000 claims description 2
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims description 2
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 claims description 2
- 108010001127 Insulin Receptor Proteins 0.000 claims description 2
- 102100036721 Insulin receptor Human genes 0.000 claims description 2
- 241000282842 Lama glama Species 0.000 claims description 2
- 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims description 2
- 108010014251 Muramidase Proteins 0.000 claims description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 102100027125 Sialic acid-binding Ig-like lectin 11 Human genes 0.000 claims description 2
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims description 2
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 2
- 230000001746 atrial effect Effects 0.000 claims description 2
- 238000012575 bio-layer interferometry Methods 0.000 claims description 2
- GBVKRUOMSUTVPW-AHNVSIPUSA-N chembl1089636 Chemical compound N([C@H]([C@@H](OC(=O)CCC(=O)N[C@@H](C(O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@H]([C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@H]([C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 GBVKRUOMSUTVPW-AHNVSIPUSA-N 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 210000003714 granulocyte Anatomy 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 229960000274 lysozyme Drugs 0.000 claims description 2
- 235000010335 lysozyme Nutrition 0.000 claims description 2
- 239000004325 lysozyme Substances 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 210000002997 osteoclast Anatomy 0.000 claims description 2
- 108010046239 paclitaxel-Angiopep-2 conjugate Proteins 0.000 claims description 2
- 108010043655 penetratin Proteins 0.000 claims description 2
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 108010011110 polyarginine Proteins 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims 17
- 239000004472 Lysine Substances 0.000 claims 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 13
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 13
- 235000018102 proteins Nutrition 0.000 claims 12
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 229940088679 drug related substance Drugs 0.000 claims 1
- 230000003828 downregulation Effects 0.000 description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 description 1
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 description 1
- 102100029957 Sialic acid-binding Ig-like lectin 5 Human genes 0.000 description 1
- 101710110535 Sialic acid-binding Ig-like lectin 5 Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023098189A JP2023134445A (ja) | 2017-08-03 | 2023-06-15 | 抗ｃｄ３３抗体及びその使用方法 |
| JP2025132557A JP2025176024A (ja) | 2017-08-03 | 2025-08-07 | 抗ｃｄ３３抗体及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541024P | 2017-08-03 | 2017-08-03 | |
| US62/541,024 | 2017-08-03 | ||
| US201862667388P | 2018-05-04 | 2018-05-04 | |
| US62/667,388 | 2018-05-04 | ||
| PCT/US2018/045056 WO2019028283A1 (en) | 2017-08-03 | 2018-08-02 | ANTI-CD33 ANTIBODIES AND METHODS OF USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023098189A Division JP2023134445A (ja) | 2017-08-03 | 2023-06-15 | 抗ｃｄ３３抗体及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532947A JP2020532947A (ja) | 2020-11-19 |
| JP2020532947A5 true JP2020532947A5 (enExample) | 2021-09-09 |
| JP7299160B2 JP7299160B2 (ja) | 2023-06-27 |
Family
ID=63245104
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559021A Active JP7299160B2 (ja) | 2017-08-03 | 2018-08-02 | 抗ｃｄ３３抗体及びその使用方法 |
| JP2023098189A Pending JP2023134445A (ja) | 2017-08-03 | 2023-06-15 | 抗ｃｄ３３抗体及びその使用方法 |
| JP2025132557A Pending JP2025176024A (ja) | 2017-08-03 | 2025-08-07 | 抗ｃｄ３３抗体及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023098189A Pending JP2023134445A (ja) | 2017-08-03 | 2023-06-15 | 抗ｃｄ３３抗体及びその使用方法 |
| JP2025132557A Pending JP2025176024A (ja) | 2017-08-03 | 2025-08-07 | 抗ｃｄ３３抗体及びその使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10711062B2 (enExample) |
| EP (1) | EP3589658A1 (enExample) |
| JP (3) | JP7299160B2 (enExample) |
| KR (1) | KR102733407B1 (enExample) |
| CN (2) | CN117700548A (enExample) |
| AU (1) | AU2018310985A1 (enExample) |
| BR (1) | BR112019023789A2 (enExample) |
| CA (1) | CA3057447A1 (enExample) |
| CL (3) | CL2019003095A1 (enExample) |
| CO (1) | CO2019012200A2 (enExample) |
| CR (1) | CR20190486A (enExample) |
| EC (1) | ECSP19078414A (enExample) |
| IL (3) | IL270238B (enExample) |
| MA (1) | MA47691A (enExample) |
| MY (1) | MY205541A (enExample) |
| PE (1) | PE20200486A1 (enExample) |
| PH (1) | PH12019502463A1 (enExample) |
| TW (1) | TW201920268A (enExample) |
| WO (1) | WO2019028283A1 (enExample) |
| ZA (1) | ZA201906366B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3307779A2 (en) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
| AU2016276981B2 (en) | 2015-06-12 | 2022-10-06 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| JP7023853B2 (ja) * | 2016-03-04 | 2022-02-22 | アレクトル エルエルシー | 抗ｔｒｅｍ１抗体及びその使用方法 |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| MY205541A (en) | 2017-08-03 | 2024-10-25 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| HUE062436T2 (hu) | 2017-08-03 | 2023-11-28 | Alector Llc | Anti-trem2 antitestek és alkalmazási módszereik |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| AR119259A1 (es) | 2018-08-31 | 2021-12-09 | Alector Llc | Anticuerpos anti-cd33 y métodos de uso de los mismos |
| JP2022501319A (ja) * | 2018-09-25 | 2022-01-06 | アカデミア シニカAcademia Sinica | 抗Ｓｉｇｌｅｃ抗体、それを備える薬学的組成物及びその使用 |
| AU2020225631A1 (en) * | 2019-02-22 | 2021-09-16 | Memorial Sloan Kettering Cancer Center | CD33 antibodies and methods of using the same to treat cancer |
| WO2020239947A1 (en) * | 2019-05-29 | 2020-12-03 | Centre National De La Recherche Scientifique | Prognosis method of leukemia |
| PH12022550239A1 (en) * | 2019-07-31 | 2022-12-19 | Alector Llc | Anti-ms4a4a antibodies and methods of use thereof |
| WO2021119400A1 (en) * | 2019-12-12 | 2021-06-17 | Alector Llc | Methods of use of anti-cd33 antibodies |
| WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
| WO2023114499A1 (en) | 2021-12-17 | 2023-06-22 | Denali Therapeutics Inc. | Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides |
| CN118633022A (zh) * | 2022-01-11 | 2024-09-10 | 雷杰纳荣制药公司 | 骨髓细胞上表达的触发受体2(trem2)变体以及其在治疗阿尔茨海默病中的用途 |
| AU2023289376A1 (en) * | 2022-06-22 | 2025-01-16 | Eli Lilly And Company | Human cd33 antibodies and glucocorticoid conjugates |
| CN117447592B (zh) * | 2022-07-26 | 2024-05-28 | 北京东方百泰生物科技股份有限公司 | 一种抗Siglec-15单克隆抗体、其抗原结合片段及其应用 |
| AU2024249778A1 (en) | 2023-04-03 | 2025-11-06 | Alchemab Therapeutics Ltd | Anti-cd33 antibodies |
| CN116375874B (zh) * | 2023-04-14 | 2023-12-26 | 上海精翰生物科技有限公司 | 一种cd33抗体及其应用 |
| WO2025174974A1 (en) * | 2024-02-14 | 2025-08-21 | Bristol-Myers Squibb Company | Anti-cd33 antibodies and uses thereof |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
| CN121673409A (zh) * | 2024-09-12 | 2026-03-17 | 安诺柏德生物医药科技(苏州)有限公司 | 靶向人cd33的人源化抗体及其应用 |
| CN120965883B (zh) * | 2025-10-21 | 2026-01-30 | 上海交通大学医学院附属仁济医院 | 一种cd33阻断性人源化抗体及用途 |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| CA1338518C (en) | 1987-09-23 | 1996-08-13 | Joyce M. Zarling | Antibody heteroconjugates for the killing of hiv-infected cells |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| EP0504327B1 (en) | 1989-12-14 | 2000-09-20 | Sloan-Kettering Institute For Cancer Research | Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| AU8295491A (en) | 1990-06-29 | 1992-01-23 | Biosource Technologies Incorporated | Melanin production by transformed microorganisms |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| DK51092D0 (da) | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| ZA932523B (en) | 1992-04-10 | 1994-10-08 | Res Dev Foundation | Immunotoxins directed against cd33 related surface antigens |
| JPH08502723A (ja) | 1992-07-27 | 1996-03-26 | ハイブライドン インコーポレイテッド | オリゴヌクレオチド・アルキルホスホノチオエート |
| DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
| AU684748B2 (en) | 1993-01-21 | 1998-01-08 | Hybridon, Inc. | Foldback triplex-forming oligonucleotides |
| US5637684A (en) | 1994-02-23 | 1997-06-10 | Isis Pharmaceuticals, Inc. | Phosphoramidate and phosphorothioamidate oligomeric compounds |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5614622A (en) | 1995-06-01 | 1997-03-25 | Hybridon, Inc. | 5-pentenoyl moiety as a nucleoside-amino protecting group, 4-pentenoyl-protected nucleotide synthons, and related oligonucleotide syntheses |
| US5962674A (en) | 1995-06-01 | 1999-10-05 | Hybridon, Inc. | Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages |
| US6140482A (en) | 1995-06-01 | 2000-10-31 | Hybridon, Inc. | Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same |
| US5955599A (en) | 1995-06-01 | 1999-09-21 | Hybridon, Inc. | Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages |
| US5637683A (en) | 1995-07-13 | 1997-06-10 | Cornell Research Foundation, Inc. | Nucleic acid analog with amide linkage and method of making that analog |
| US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
| WO1997011971A1 (en) | 1995-09-28 | 1997-04-03 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US6117992A (en) | 1996-08-26 | 2000-09-12 | Hybridon, Inc. | Reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleoside linkages |
| US5886165A (en) | 1996-09-24 | 1999-03-23 | Hybridon, Inc. | Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US5739314A (en) | 1997-04-25 | 1998-04-14 | Hybridon, Inc. | Method for synthesizing 2'-O-substituted pyrimidine nucleosides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| IL145496A0 (en) | 1999-03-24 | 2002-06-30 | Exiqon As | Improved synthesis of [2.2.1] bicyclo nucleosides |
| KR20010001577A (ko) | 1999-06-07 | 2001-01-05 | 윤종용 | 고분자 광산발생제를 이용한 올리고펩티드 핵산 탐침의 제조방법 |
| AU6629200A (en) | 1999-08-25 | 2001-03-19 | Philip P Garner | Alpha-helical peptide nucleic acid alpha-pna |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US6455308B1 (en) | 2001-08-01 | 2002-09-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of serum amyloid A4 expression |
| US20030206916A1 (en) | 2002-05-03 | 2003-11-06 | Rush-Presbyterian-St. Luke's Medical Center | Immunogenic peptides |
| WO2004042072A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| DK1578446T3 (en) | 2002-11-07 | 2015-06-29 | Immunogen Inc | ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| BRPI0518994A2 (pt) | 2004-12-31 | 2008-12-02 | Biogen Idec Inc | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas |
| EP2361933A3 (en) | 2005-01-26 | 2012-05-02 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| TW200726776A (en) | 2005-07-29 | 2007-07-16 | Friedrich Alexander University Of Erlangen Nuremberg | CD33-specific single-chain immunotoxin and methods of use |
| US7420040B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| US20110038856A1 (en) | 2006-11-02 | 2011-02-17 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
| US8465741B2 (en) * | 2006-12-20 | 2013-06-18 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| WO2009036379A2 (en) | 2007-09-14 | 2009-03-19 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| AU2010298036B2 (en) | 2009-09-25 | 2015-05-21 | Xoma Technology Ltd. | Screening methods |
| DE102009045006A1 (de) | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| EP2560994B1 (en) * | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
| MX381912B (es) | 2010-07-16 | 2025-03-13 | Adimab Llc | Colecciones de anticuerpos. |
| UA112062C2 (uk) * | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| WO2012074097A1 (ja) | 2010-12-03 | 2012-06-07 | 協和発酵キリン株式会社 | 抗ｃｄ３３抗体 |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| CN102952191B (zh) | 2012-09-17 | 2014-05-14 | 浙江大学 | 全人源抗cd33单链抗体zjl101及其应用 |
| DK2935331T3 (en) * | 2012-12-24 | 2018-06-06 | Abbvie Inc | PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF |
| EP2978446B1 (en) | 2013-03-27 | 2020-03-04 | The General Hospital Corporation | Anti-cd33 antibody for use in treating alzheimer's disease |
| BR112016002753A2 (pt) * | 2013-08-13 | 2017-11-21 | Sanofi Sa | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos |
| AR098743A1 (es) | 2013-12-13 | 2016-06-08 | Genentech Inc | Anticuerpos e inmunoconjugados anti-cd33 |
| AR101669A1 (es) | 2014-07-31 | 2017-01-04 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| AU2015357054A1 (en) | 2014-12-04 | 2017-06-29 | Abruzzo Theranostic S.R.L. | Humanized anti-Trop-2 monoclonal antibodies and uses thereof |
| EP3307779A2 (en) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
| AU2016276981B2 (en) * | 2015-06-12 | 2022-10-06 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| US9914781B1 (en) * | 2016-11-08 | 2018-03-13 | Glaxosmithkline Intellectual Property Development Limited | Binding agonist for treatment of neurological and other disorders |
| MY205541A (en) * | 2017-08-03 | 2024-10-25 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| AR119259A1 (es) | 2018-08-31 | 2021-12-09 | Alector Llc | Anticuerpos anti-cd33 y métodos de uso de los mismos |
-
2018
- 2018-08-02 MY MYPI2019006405A patent/MY205541A/en unknown
- 2018-08-02 CN CN202311258379.1A patent/CN117700548A/zh active Pending
- 2018-08-02 MA MA047691A patent/MA47691A/fr unknown
- 2018-08-02 WO PCT/US2018/045056 patent/WO2019028283A1/en not_active Ceased
- 2018-08-02 AU AU2018310985A patent/AU2018310985A1/en not_active Abandoned
- 2018-08-02 KR KR1020197035734A patent/KR102733407B1/ko active Active
- 2018-08-02 JP JP2019559021A patent/JP7299160B2/ja active Active
- 2018-08-02 CN CN201880027790.9A patent/CN110662765B/zh active Active
- 2018-08-02 CR CR20190486A patent/CR20190486A/es unknown
- 2018-08-02 BR BR112019023789-5A patent/BR112019023789A2/pt not_active IP Right Cessation
- 2018-08-02 EP EP18756115.4A patent/EP3589658A1/en active Pending
- 2018-08-02 PE PE2019002182A patent/PE20200486A1/es unknown
- 2018-08-02 CA CA3057447A patent/CA3057447A1/en active Pending
- 2018-08-03 TW TW107127182A patent/TW201920268A/zh unknown
- 2018-08-03 US US16/054,840 patent/US10711062B2/en active Active
-
2019
- 2019-09-26 ZA ZA2019/06366A patent/ZA201906366B/en unknown
- 2019-10-28 CL CL2019003095A patent/CL2019003095A1/es unknown
- 2019-10-28 IL IL270238A patent/IL270238B/en unknown
- 2019-10-30 CO CONC2019/0012200A patent/CO2019012200A2/es unknown
- 2019-10-31 EC ECSENADI201978414A patent/ECSP19078414A/es unknown
- 2019-10-31 PH PH12019502463A patent/PH12019502463A1/en unknown
-
2020
- 2020-05-07 US US16/869,315 patent/US11254743B2/en active Active
- 2020-06-16 CL CL2020001619A patent/CL2020001619A1/es unknown
-
2021
- 2021-12-28 CL CL2021003535A patent/CL2021003535A1/es unknown
-
2022
- 2022-01-16 IL IL289882A patent/IL289882A/en unknown
- 2022-01-16 IL IL289880A patent/IL289880A/en unknown
- 2022-01-21 US US17/581,471 patent/US20220162309A1/en active Pending
-
2023
- 2023-06-15 JP JP2023098189A patent/JP2023134445A/ja active Pending
-
2025
- 2025-08-07 JP JP2025132557A patent/JP2025176024A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111148761B (zh) | 多特异性抗体及其制备和使用方法 | |
| JP7575100B2 (ja) | 免疫細胞活性化のための二重特異性抗体 | |
| JP2020533948A5 (enExample) | ||
| JP2021529520A5 (enExample) | ||
| KR20180130574A (ko) | 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법 | |
| CN117777267A (zh) | 具有SIRP-α结构域或其变体的构建体 | |
| US20230340157A1 (en) | Monospecific and multi-specific antibodies | |
| CN116041530A (zh) | 多特异性抗体及其制备和使用方法 | |
| CN117946277A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2022527994A (ja) | 三重特異性結合性タンパク質、方法、およびその使用 | |
| TW202200618A (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| JP2024522069A (ja) | Ｉｌ－２１ポリペプチド及び標的化コンストラクト | |
| JP2022542964A5 (enExample) | ||
| JP7834075B2 (ja) | トランスサイレチン免疫グロブリン融合物 | |
| CN117751144A (zh) | 抗cd38抗体、抗cd3抗体和双特异性抗体以及它们的用途 | |
| US20240124574A1 (en) | Bispecific Antibodies with Charge Pairs and Uses Thereof | |
| US20110257373A1 (en) | Ligands that have binding specificity for dc-sign | |
| WO2024085166A1 (ja) | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 | |
| HK40108172A (en) | Constructs having a sirp-alpha domain or variant thereof | |
| HK40102926A (en) | Bispecific antibodies with charge pairs and uses thereof | |
| JP2026514818A (ja) | 活性化可能な二特異性抗ｃｄ２８および抗ｐｄ－ｌ１タンパク質ならびにそれらの使用 | |
| WO2025101526A1 (en) | Multi-specific cancer-targeting antibodies | |
| HK40100726A (en) | Anti-tigit antibodies and uses thereof | |
| CN118804928A (zh) | 用于与pd-1x ctla-4双特异性分子组合使用b7-h3抗体-药物缀合物的方法 | |
| CN117015556A (zh) | 带电荷对的双特异性抗体及其应用 |